Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4904]

There’s a better way to detect high-risk medications in older adults with cancer according to new study

There’s a better way to detect high-risk medications in older adults with cancer according to new study

Skin cancer cells harness nerve cell gene to drill through and invade new tissues

Skin cancer cells harness nerve cell gene to drill through and invade new tissues

All patients’ cancers should be genetically profiled to improve care, say leading health experts

All patients’ cancers should be genetically profiled to improve care, say leading health experts

European head and neck society issues recommendations for head and neck cancer survivorship care

European head and neck society issues recommendations for head and neck cancer survivorship care

WCLC 2022: Chinese researchers develop lung cancer risk prediction nomogram for female non - smokers

WCLC 2022: Chinese researchers develop lung cancer risk prediction nomogram for female non - smokers

Olaparib for high-risk, early-stage breast cancer approved in Europe

Olaparib for high-risk, early-stage breast cancer approved in Europe

WCLC 2022: Association between KRAS/STK11/KEAP1 mutations and outcomes in POSEIDON: Durvalumab ± tremelimumab + chemotherapy in mNSCLC

WCLC 2022: Association between KRAS/STK11/KEAP1 mutations and outcomes in POSEIDON: Durvalumab ± tremelimumab +...

WCLC 2022: Consolidation nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III NSCLC

WCLC 2022: Consolidation nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiation for...

Budget impact analysis demonstrates NELSON screening model would save more than 18,000 premature lung cancer deaths

Budget impact analysis demonstrates NELSON screening model would save more than 18,000 premature lung cancer deaths

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer

FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer

More from ecancer